Euglycemic infusion of insulin detemir compared with human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects

Diabetes

Volumn 59, Issue 4, 2010, Pages 1101-1107

  Hallschmid, Manfred ^a   Jauch Chara, Kamila ^a   Korn, Oliver ^a   Mölle, Matthias ^a   Rasch, Björn ^a   Born, Jan ^a   Schultes, Bernd ^a,b   Kern, Werner ^a,c  

^a UNIVERSITY OF LÜBECK   (Germany)

^b Interdisciplinary Obesity Center   (Switzerland)

^c MVZ Endokrinologikum Ulm   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HUMAN INSULIN; INSULIN; INSULIN DETEMIR;

ADULT; ARTICLE; BRAIN FUNCTION; CALORIC INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIRECT CURRENT; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; ELECTROENCEPHALOGRAPHY; FOOD COMPOSITION; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE HOMEOSTASIS; GLUCOSE INFUSION; HUMAN; HUMAN EXPERIMENT; HYPERINSULINEMIA; MALE; MOOD CHANGE; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; STEADY STATE; WEIGHT GAIN;

ADULT; AFFECT; BLOOD GLUCOSE; BRAIN; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; ELECTROOCULOGRAPHY; ENERGY INTAKE; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; INSULIN; MALE;

EID: 77951150702     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db09-1493     Document Type: Article

References (39)

1. Woods SC, Seeley RJ, Baskin DG, Schwartz MW. Insulin and the blood-brain barrier. Curr Pharm Des 2003;9:795-800
2. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature 2006;443: 289-295
3. Woods SC, Lotter EC, McKay LD, Porte D Jr. Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons. Nature 1979;282:503-505
4. Clegg DJ, Riedy CA, Smith KA, Benoit SC, Woods SC. Differential sensitivity to central leptin and insulin in male and female rats. Diabetes 2003;52:682-687
5. Benedict C, Kern W, Schultes B, Born J, Hallschmid M. Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin. J Clin Endocrinol Metab 2008;93:1339-1344
6. Hallschmid M, Benedict C, Schultes B, Fehm HL, Born J, Kern W. Intranasal insulin reduces body fat in men but not in women. Diabetes 2004;53:3024-3029
7. Kurtzhals P. Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir. Int J Obes Relat Metab Disord 2004;28(Suppl. 2):S23-S28
8. Kurtzhals P, Schäffer L, Sørensen A, Kristensen C, Jonassen I, Schmid C, Trüb T. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000;49: 999-1005
9. De Leeuw I, Vague P, Selam JL, Skeie S, Lang H, Draeger E, Elte JW. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005;7:73-82
10. Heise T, Nosek L, Rønn BB, Endahl L, Heinemann L, Kapitza C, Draeger E. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53:1614-1620
11. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269-1274
12. Raslovà K, Bogoev M, Raz I, Leth G, Gall MA, Hâncu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004;66:193-201
13. Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P, Landin-Olsson M, Hylleberg B, Lang H, Draeger E, Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004;27:1081-1087
14. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004;47:622-629
15. Tschritter O, Hennige AM, Preissl H, Porubska K, Schafer SA, Lutzenberger W, Machicao F, Birbaumer N, Fritsche A, Haring HU. Cerebrocortical beta activity in overweight humans responds to insulin detemir. PLoS One 2007;2:e1196
16. Rossetti P, Porcellati F, Ricci NB, Candeloro P, Cioli P, Bolli GB, Fanelli CG. Different brain responses to hypoglycemia induced by equipotent doses of the long-acting insulin analog detemir and human regular insulin in humans. Diabetes 2008;57:746-756
17. Tschritter O, Schafer SA, Klett J, Pfafflin A, Haring HU, Hennige AM, Fritsche A. Insulin detemir causes increased symptom awareness during hypoglycaemia compared to human insulin. Diabetes Obes Metab 2009;11: 1017-1026
18. Tschritter O, Preissl H, Hennige AM, Stumvoll M, Porubska K, Frost R, Marx H, Klösel B, Lutzenberger W, Birbaumer N, Häring HU, Fritsche A. The cerebrocortical response to hyperinsulinemia is reduced in overweight humans: a magnetoencephalographic study. Proc Natl Acad Sci U S A 2006;103:12103-12108
19. Hallschmid M, Schultes B. Central nervous insulin resistance: a promising target in the treatment of metabolic and cognitive disorders? Diabetologia 2009;52:2264-2269
20. Hallschmid M, Benedict C, Schultes B, Born J, Kern W. Obese men respond to cognitive but not to catabolic brain insulin signaling. Int J Obes (Lond) 2008;32:275-282
21. Hallschmid M, Schultes B, Marshall L, Mölle M, Kern W, Bredthauer J, Fehm HL, Born J. Transcortical direct current potential shift reflects immediate signaling of systemic insulin to the human brain. Diabetes 2004;53:2202-2208
22. Pietrowsky R, Preuss S, Born J, Pauschinger P, Fehm HL. Effects of cholecystokinin and calcitonin on evoked brain potentials and satiety in man. Physiol Behav 1989;46:513-519
23. Janke W, Debus G. Die Eigenschaftswörterliste (EWL). Göttingen, Germany, Hogrefe, 1978
24. Marshall L, Mölle M, Fehm HL, Born J. Scalp recorded direct current brain potentials during human sleep. Eur J Neurosci 1998;10:1167-1178
25. Schmitt B, Mölle M, Marshall L, Born J. Scalp recorded direct current potential shifts associated with quenching thirst in humans. Psychophysiology 2000;37:766-776
26. Guthrie D, Buchwald JS. Significance testing of difference potentials. Psychophysiology 1991;28:240-244
27. Wellhoener P, Fruehwald-Schultes B, Kern W, Dantz D, Kerner W, Born J, Fehm HL, Peters A. Glucose metabolism rather than insulin is a main determinant of leptin secretion in humans. J Clin Endocrinol Metab 2000;85:1267-1271
28. Fruehwald-Schultes B, Oltmanns KM, Kern W, Born J, Fehm HL, Peters A. The effect of experimentally induced insulin resistance on the leptin response to hyperinsulinaemia. Int J Obes Relat Metab Disord 2002;26: 510-516
29. Kum W, Zhu SQ, Ho SK, Young JD, Cockram CS. Effect of insulin on glucose and glycogen metabolism and leucine incorporation into protein in cultured mouse astrocytes. Glia 1992;6:264-268
30. Fields RD, Stevens-Graham B. New insights into neuron-glia communication. Science 2002;298:556-562
31. Heinemann U, Lux HD, Marciani MG, Hofmeier G. Slow potentials in relation to changes in extracellular potassium activity in the cortex of cats. In Origin of Cerebral Field Potentials. Speckmann EJ, Caspers H (Eds.). Stuttgart, Germany, Georg Thieme Publishers, 1979, p. 33-43
32. Hennige AM, Sartorius T, Tschritter O, Preissl H, Fritsche A, Ruth P, Häring HU. Tissue selectivity of insulin detemir action in vivo. Diabetologia 2006;49:1274-1282
33. Pardridge WM. Transport of insulin-related peptides and glucose across the blood-brain barrier. Ann N Y Acad Sci 1993;692:126-137
34. Schmitt B, Mölle M, Marshall L, Hallschmid M, Born J. Scalp recorded direct current (DC) potential shifts associated with food intake in hungry humans. Behav Brain Res 2001;119:85-92
35. Kern W, Peters A, Fruehwald-Schultes B, Deininger E, Born J, Fehm HL. Improving influence of insulin on cognitive functions in humans. Neuroendocrinology 2001;74:270-280
36. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes: causes, effects and coping strategies. Diabetes Obes Metab 2007;9:799-812
37. Wing RR, Klein R, Moss SE. Weight gain associated with improved glycemic control in population-based sample of subjects with type I diabetes. Diabetes Care 1990;13:1106-1109
38. Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086
39. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51:408-416